ES2197792B1 - Formulaciones farmaceuticas que contienen morfina intranasal. - Google Patents

Formulaciones farmaceuticas que contienen morfina intranasal.

Info

Publication number
ES2197792B1
ES2197792B1 ES200150086A ES200150086A ES2197792B1 ES 2197792 B1 ES2197792 B1 ES 2197792B1 ES 200150086 A ES200150086 A ES 200150086A ES 200150086 A ES200150086 A ES 200150086A ES 2197792 B1 ES2197792 B1 ES 2197792B1
Authority
ES
Spain
Prior art keywords
morphine
formulation
formulations containing
pharmaceutical formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200150086A
Other languages
English (en)
Other versions
ES2197792A1 (es
Inventor
Raja G. Jorge C Achari
Charanjit R. Ramneik Behl
D. Demeireles Vincent
P Dua Anthony
Romeo
Sileno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of ES2197792A1 publication Critical patent/ES2197792A1/es
Application granted granted Critical
Publication of ES2197792B1 publication Critical patent/ES2197792B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones farmacéuticas que contienen morfina intranasal.
Formulación farmacéutica para la administración intranasal que contiene morfina op una sal farmacéuticamente aceptable de la misma, con un pH que oscila entre 3,0 y 7,0, y que en cantidad terapéuticamente eficaz sirve para obtener una respuesta analfésica o anestésica en un mamífero. Dicha formulación puede contener morfina o sal farmacéuticamente aceptable de la misma, en combinación con un sistema de administración nasal, dispersante en una formulación acuosa o no acuosa, suspensiones, soluciones, polvos, geles, ungüentos y cremas. El sistema de administración nasal comprende un tempón para mantener el pH de la morfina o de una sal farmacéuticamente aceptable de la misma, un agente espesante, un humectante, un intensificador de la absorción y combinaciones de los mismos. La formulación comprende además uno o más excipientes farmacéuticos y un conservante.
ES200150086A 1999-06-16 2000-05-23 Formulaciones farmaceuticas que contienen morfina intranasal. Expired - Lifetime ES2197792B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
US09/334537 1999-06-16

Publications (2)

Publication Number Publication Date
ES2197792A1 ES2197792A1 (es) 2004-01-01
ES2197792B1 true ES2197792B1 (es) 2005-05-01

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200150086A Expired - Lifetime ES2197792B1 (es) 1999-06-16 2000-05-23 Formulaciones farmaceuticas que contienen morfina intranasal.

Country Status (30)

Country Link
US (1) US6677346B1 (es)
EP (2) EP1419774A1 (es)
JP (1) JP2003501467A (es)
KR (1) KR20020016831A (es)
AU (1) AU774175B2 (es)
BG (1) BG106221A (es)
BR (1) BR0012082A (es)
CA (1) CA2374877C (es)
CZ (1) CZ20014399A3 (es)
DE (1) DE10084709T1 (es)
DK (1) DK200101859A (es)
EE (1) EE200100677A (es)
ES (1) ES2197792B1 (es)
FI (1) FI20012462A (es)
GB (1) GB2367005A (es)
HR (1) HRP20010926A2 (es)
HU (1) HUP0201856A3 (es)
IS (1) IS6202A (es)
LT (1) LT4976B (es)
LU (1) LU90859B1 (es)
LV (1) LV12859B (es)
MX (1) MXPA01012879A (es)
NO (1) NO20015931L (es)
NZ (1) NZ515783A (es)
PL (1) PL352556A1 (es)
SE (1) SE0104203L (es)
SI (1) SI20850A (es)
SK (1) SK18172001A3 (es)
TR (1) TR200103613T2 (es)
WO (1) WO2000076506A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP2009506076A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
ME02958B (me) 2011-05-13 2018-07-20 Euro Celtique Sa Intranazalni farmaceutski dozni oblici коji obuhvataju nalokson
WO2014016653A1 (en) 2012-07-26 2014-01-30 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (en) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
RS65034B1 (sr) 2015-01-07 2024-02-29 Tonix Pharma Ltd Formulacije oksitocina koje sadrže magnezijum i postupci za njihovu upotrebu
AU2017345765A1 (en) * 2016-10-21 2019-06-06 Somniferum Labs LLC Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction
KR102660711B1 (ko) * 2017-10-20 2024-04-26 키에시 파르마슈티시 엣스. 피. 에이. 활성 성분으로서 오피오이드 수용체 효능제를 포함하는 약제학적 제제, 그의 제조 방법 및 치료적 사용
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 ***鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
ATE290864T1 (de) * 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5874450A (en) * 1996-09-27 1999-02-23 Nastech Pharmaceutical Company, Inc. Intranasal formulations for promoting sleep and method of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERWEIJ, S.L. et al. Can morphine be administered nasally?. Ziekenhuisfarmacie, 1988, nº 4, páginas 73-77. *

Also Published As

Publication number Publication date
EP1183027A1 (en) 2002-03-06
ES2197792A1 (es) 2004-01-01
CZ20014399A3 (cs) 2002-06-12
DE10084709T1 (de) 2002-09-26
BG106221A (en) 2002-08-30
EP1183027A4 (en) 2003-02-05
NZ515783A (en) 2004-05-28
SE0104203D0 (sv) 2001-12-14
GB0128383D0 (en) 2002-01-16
EP1419774A1 (en) 2004-05-19
WO2000076506A1 (en) 2000-12-21
HRP20010926A2 (en) 2003-04-30
DK200101859A (da) 2001-12-12
HUP0201856A3 (en) 2004-12-28
AU774175B2 (en) 2004-06-17
NO20015931L (no) 2002-02-08
PL352556A1 (en) 2003-08-25
AU5156100A (en) 2001-01-02
CA2374877A1 (en) 2000-12-21
MXPA01012879A (es) 2003-06-24
JP2003501467A (ja) 2003-01-14
IS6202A (is) 2001-12-14
SK18172001A3 (sk) 2002-07-02
CA2374877C (en) 2004-04-13
KR20020016831A (ko) 2002-03-06
HUP0201856A1 (en) 2002-09-28
SI20850A (sl) 2002-10-31
FI20012462A (fi) 2002-01-16
SE0104203L (sv) 2001-12-14
EE200100677A (et) 2003-02-17
GB2367005A (en) 2002-03-27
BR0012082A (pt) 2002-05-07
LV12859B (en) 2002-12-20
LT4976B (lt) 2002-12-30
LT2001119A (en) 2002-07-25
US6677346B1 (en) 2004-01-13
NO20015931D0 (no) 2001-12-04
TR200103613T2 (tr) 2004-08-23
LU90859B1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
ES2197792B1 (es) Formulaciones farmaceuticas que contienen morfina intranasal.
CA2348869A1 (en) Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
EA200000629A1 (ru) Стабилизированные растворы терипаратида
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
AR092919A2 (es) Composicion farmaceutica liquida
NL300281I2 (nl) Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
DE69810481T2 (de) Stabilisierte antikörperformulierung
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
WO2001041550A3 (en) Topical anesthetic formulation
AR027554A1 (es) Nuevo sistema de adminstracion de farmacos autoemulsionante
NO943070L (no) Antitussiva
DK0647129T3 (da) Præparat til topisk anvendelse
AR031010A1 (es) Una composicion farmaceutica, util para inhibir el dano celular
ATE316376T1 (de) Neue pharmazeutische zusammenstellung und deren herstellungsprozess
SE8009102L (sv) Estrar av l-arginin for anvendning vid behandling av akut lungodem, vissa chocktillstand och hyperfibrinolys
HK1012242A1 (en) Topical composition containing penciclovir
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
DE60135845D1 (de) Pralmorelin-haltige nasentropfen-präparate
ECSP993206A (es) Metodo para mejorar la farmacocinetica del tipranavir
EA200000168A1 (ru) Фармацевтическая композиция, снижающая продуцирование белка мср-1
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제
TH20307A (th) สารสูตรผสมอิมัลชันชนิดใหม่

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197792B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20051018